Protein kinases are important regulators of cellular proliferation and several, such as HER-2/neu, and the epidermal growth factor receptor (EGFR), have been implicated in the pathogenesis and progression of human breast cancer. We have speculated that other kinases expressed in breast cancer cells may have important functions in the genesis or maintenance of the malignant state. For this reason, we have completed a search for novel kinases in breast cancer tissue and have identified several potentially important species: Our work with the focal adhesion kinase (FAK) is among the more advanced subprojects. We have found that FAK expression is correlated with the invasive and metastatic phenotype and thus may represent a useful marker in early stage breast cancer. Moreover, specific attenuation of FAK expression by antisense oligonucleotides induces apoptosis in cancer cell lines making FAK a rational target for gene directed therapeutics. rak is a src related tyrosine kinase with a nuclear localization signal within its SH2 domain, rak is a unique nuclear tyrosine kinase that binds to the retinoblastoma gene protein, Rb, through its SH3 domain. This implicates rak in cell cycle control and potentially in transformation. STK1 is the human homolog of the cdc2 activating kinase (CAK) which is essential for cdc2/cyclin function. Our investigations show that inhibition of CAK expression results in attenuation of growth in a breast cancer cell line. TK5 is a new JAK kinase, JAK3, expressed in primary breast cancer cells and cell lines, and which is also the important kinase partner for the IL-2/IL-4 receptor. Our discovery of different splice forms with one leading to an enzymatically inactive JAK3 kinase suggests complex signalling through potentially novel cytokine receptors. In this proposal we will focus upon FAK, rak and CAK, characterizing the role of these novel species in breast cancer biology especially in growth and differentiation and to using this knowledge in the design of more specific and directed therapies for breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058223-04
Application #
3731489
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386
Nasarre, Patrick; Bonilla, Ingrid V; Metcalf, John S et al. (2018) TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma. Melanoma Res 28:185-194
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319
Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32
Couture, Heather D; Williams, Lindsay A; Geradts, Joseph et al. (2018) Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. NPJ Breast Cancer 4:30
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12

Showing the most recent 10 out of 598 publications